Skip to main content
Signal8
Launch Terminal

Yarrow Bioscience, Inc. (YARW)

Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).

Sector: Pharmaceutical Preparations

Industry: Biotechnology

Yarrow Bioscience Inc logo

Yarrow Bioscience Inc

NASDAQ:YARWHealthcare
-0.50%$19.90
AH$19.90+0.00%vs close
Mkt Cap$185.16M
Float9.3M
O/S9.3M
Vol
$ Vol
RVOL
Inst Own2.9%
Earnings
Div Yield101.00%
Dilution
Yarrow Bioscience Inc logoNASDAQ:YARW$19.90-0.50%
FormDescription
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
4
OWNERSHIP DOCUMENT
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
1
8-K
1.01,9.01
3
424B5
Prospectus Supplement
7
424B5
Prospectus Supplement
8
8-K
8.01,9.01
7
EFFECT
Notice of Effectiveness
2
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
POS AM
Post-Effective Amendment
4
8-K/A
2.02,7.01,9.01
6
10-Q
Quarterly Report
6
13G/A
Beneficial Ownership Report (Amended)
13G/A
Beneficial Ownership Report (Amended)
13G
Beneficial Ownership Report
13D
Beneficial Ownership Report (Active)
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
13G
Beneficial Ownership Report
4
OWNERSHIP DOCUMENT

1-25 of 682

…